Browse by Subjects
Lung Cancer

This Entry collection belongs to a new joint type of Special Issue published on Life journal and Encyclopedia platfrom, Dr. Hugo Arasanz Esteban and Dr. Paula Aldaz serve as the Guest Editors, focused original entry are welcome in this Entry collection, all entries can be published for free. You can get more information from the website of special issue about this topic: https://www.mdpi.com/journal/life/special_issues/immunotherapy_lung_cancer

Submit
Sort:
Show:
Page Size:
Topic review
Updated time: 22 Apr 2021
Submitted by: Elien Augustus
Definition: Currently, the only validated companion diagnostic test for first-line immunotherapy in metastatic NSCLC patients is testing for programmed death ligand 1 (PD-L1) expression in tumor tissues. However, obtaining tumor tissue can be challenging and it puts the patient at risk. Liquid biopsy offers an alternative, less invasive approach to select NSCLC patients who would benefit from immunotherapy and to monitor patients during their disease course. Liquid biopsy allows repetitive sampling, which makes it a useful tool in clinical practice.
Entry Collection : Lung Cancer
Unfold
Topic review
Updated time: 13 Apr 2021
Submitted by: Delphine Quatannens
Definition: Cancer-associated fibroblasts (CAFs) are prominent and key components of the TME in most types of solid tumors. Extensive research over the past decade revealed their ability to modulate cancer metastasis, angiogenesis, tumor mechanics, immunosuppression, and drug access through synthesis and remodeling of the extracellular matrix and production of growth factors. Thus, they are considered to impede the response to current clinical cancer therapies. Therefore, targeting CAFs to counteract these protumorigenic effects, and overcome the resistance to current therapeutic options, is an appealing and emerging strategy.
Entry Collection : Lung Cancer
Unfold
Topic review
Updated time: 06 Apr 2021
Submitted by: Lucia Anna Muscarella
Definition: Small-cell lung cancer (SCLC) is an aggressive type of cancer with an incidence of about 15% among lung cancers and has a very poor prognosis due to its rapid development of resistance to chemo- and radiotherapies. Unlike the increase in personalized approaches to the clinical care of patients with non-small-cell lung cancer (NSCLC), clinical protocols for SCLC still mainly depend on the stage of the disease, prior therapies, and lack of specific molecular support. This approach was mainly due to the idea of SCLC as a monolithic entity with common genetic features, which was strictly linked to the lack of an adequate quantity of tissue samples in this inoperable class of patients, for the lack of a clear and comprehensive biological profile presented an obstacle.
Entry Collection : Lung Cancer
Unfold